Author/Authors :
Ramezani, Alireza Ophthalmic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Fard Esmaeilpour, Nassim Ophthalmic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Eskandari, Armen Ophthalmic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Rabbanikhah, Zahra Ophthalmic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Soheilian, Roham Ophthalmic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Soheilian, Masoud Ophthalmic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
Purpose: To evaluate the effect of a single dose of intravitreal diclofenac on bestcorrected visual acuity (BCVA) and central macular thickness (CMT) in patients with refractory uveitic cystoid macular edema (CME).
Methods: In this prospective non-comparative case series, 8 eyes of 8 patients with
refractory CME secondary to chronic intermediate uveitis received a single intravitreal
injection of diclofenac (500 μg/0.1ml) in addition to other systemic (oral prednisolone
and methotraxate) and topical (betamethasone) remission maintaining drugs. Outcome measures were changes in BCVA and CMT after treatment.
Results: Mean BCVA remained relatively unchanged at 12, 24 and 36 weeks (0.69, 0.70 and 0.64 LogMAR, respectively) as compared to baseline (0.71 LogMAR). Mean CMT, however, decreased from 488 μm at baseline to 416 and 456 μm at 24 and 36 weeks, respectively. None of the changes were statistically significant.
Conclusion: In eyes with refractory uveitic CME, intravitreal injection of diclofenac
insignificantly reduced CMT but this was not associated with visual improvement.
Keywords :
Cystoid Macular Edema , Diclofenac Sodium , Intravitreal Injection , Visual Acuity , Uveitis
